Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
IPO Year: 2020
Exchange: NASDAQ
Website: sprucebiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/14/2024 | Buy → Neutral | Guggenheim | |
| 3/14/2024 | $9.00 → $2.00 | Outperform → Market Perform | Leerink Partners |
| 3/14/2024 | $9.00 → $2.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 3/14/2024 | Buy → Neutral | Ladenburg Thalmann | |
| 3/14/2024 | Buy → Neutral | H.C. Wainwright | |
| 2/21/2024 | $10.00 | Buy | Guggenheim |
| 3/8/2022 | $6.00 | Buy | Ladenburg Thalmann |
| 12/17/2021 | $15.00 | Outperform | Oppenheimer |
| 12/10/2021 | $7.00 | Speculative Buy | Benchmark |
| 12/10/2021 | $7.00 | Speculative Buy | The Benchmark Company |
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
10-Q - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
10-Q - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
Topline Data from CAHmelia-204 Study of Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Anticipated in December 2024 Topline Data from CAHptain-205 Study of Tildacerfont in Adult and Pediatric CAH Anticipated in December 2024 Cash Runway Through the End of 2025 Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2024 and provided corporate updates. "We remain on track to report primary efficacy and safety data plus interim data from the open-
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 3:30 p.m. ET. Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company's investor relations website for approximately 90 days. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company focuse
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 4:30 p.m. ET. Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company's investor relations website for approximately 90 days. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company
Announced Strategic Collaboration with HMNC Brain Health GmbH (HMNC) to Develop Tildacerfont for the Treatment of Major Depressive Disorder (MDD) Topline Data from CAHmelia-204 Study of Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Anticipated in Q4 2024 Topline Data from CAHptain-205 Study of Tildacerfont in Adult and Pediatric CAH Anticipated in Q4 2024 Cash Runway Through the End of 2025 Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Business Journal have recognized the company as a Best Place to Work in 2024. "We are thrilled to be named as a Best Place to Work in the Bay Area, which is a testament to our unwavering dedication to cultivating a mission-driven company culture underlying our core values of trust, innovation, ownership and diversity," said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, Spruce Biosciences. "Our te
Pairs Spruce's Investigational Product Candidate, Tildacerfont, with HMNC's Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF1 Receptor Antagonism Provides Spruce with Option to In-License Exclusive Worldwide Rights to Cortibon Following Completion of Phase 2 Proof-of-Concept Study HMNC to Initiate Phase 2 Study for the Treatment of MDD in Q4 2024 Spruce Biosciences, Inc. (NASDAQ:SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, and HMNC Brain Health GmbH ("HMNC"), a global precision
Significant Reduction in Dehydroepiandrosterone Sulfate (DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels at Baseline Increase in Serum Sex Hormone Binding Globulin (SHBG) Versus Placebo Observed Tildacerfont was Well-Tolerated with No Safety Signals Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine disorders with significant unmet medical need, presented results from its Phase 2 POWER study of tildacerfont, a second-generation CRF1 receptor antagonist, for the treatment of polycystic ovary syndrome (PCOS) at the 2024 Annual Meeting of the Endocrine Society (ENDO 2024
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 5:00 p.m. ET. Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company's investor relations website for approximately 90 days. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercial
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that three submitted abstracts were accepted for the 106th Annual Meeting of the Endocrine Society (ENDO 2024) taking place June 1-4, 2024, in Boston. In a poster presentation, the company will present final results from its Phase 2 POWER study of tildacerfont for the treatment of polycystic ovary syndrome (PCOS). In two other poster presentations, the company will highlight the comorbidities associated with congenital adrenal hyperplasia (CAH) and standard of care treatmen
Analyses of Data from CAHmelia-203 in Adult Congenital Adrenal Hyperplasia (CAH) Demonstrate Correlation Between Tildacerfont Response and Baseline Glucocorticoid (GC) Dose and Drug Compliance Posters Highlighting Baseline Characteristics from the CAHmelia Program in Adult CAH and CAHptain-205 Study in Pediatric CAH Presented at the Pediatric Endocrine Society (PES) 2024 Annual Meeting Topline Data from the CAHmelia-204 Study in Adult CAH and Additional Dose-Ranging Data from Adults and Children with CAH in CAHptain-205 Anticipated in Q3 2024 Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rar
CAHmelia-203 Study of Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia (CAH) with Severe Hyperandrogenemia Did Not Meet Primary Efficacy Endpoint Positive Data from CAHptain-205 Study of Tildacerfont in Pediatric Classic CAH Supports Further Dose-Ranging Across Additional Dosing Cohorts Topline Results from CAHmelia-204 Study of Tildacerfont in Adult Classic CAH Evaluating Glucocorticoid (GC) Reduction Anticipated in Third Quarter of 2024 Resource Prioritization and Cost Reductions Extend Cash Runway Through End of 2025 Conference Call Today at 4:30 p.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commerci
Spruce Reports Interim Data from Phase 2 POWER Proof-of-Concept Study in Polycystic Ovary Syndrome (PCOS) CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Surpasses 75% Enrollment in CAHmelia-203 and Approaches 75% Enrollment in CAHmelia-204 Screening Underway for Cohort 3 in CAHptain Study for Pediatric Classic CAH Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates. "Our goal with the POWER study is to ass
Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Percival Barretto-Ko to the company's Board of Directors. Concurrently, Dina Chaya, Ph.D., has stepped down from the Board of Directors. "On behalf of Spruce, I am pleased to welcome Percival Barretto-Ko to our Board of Directors," said Mike Grey, Executive Chairman of Spruce Biosciences. "Percival is an accomplished and
CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Achieves 50% Enrollment in CAHmelia-204 and Approaches 75% Enrollment in CAHmelia-203 Enrollment in P.O.W.E.R. Study for Polycystic Ovary Syndrome (PCOS) Complete – Topline Results Anticipated in Q3 2023 Cohort 1 for Phase 2 CAHptain Study in Pediatric Classic CAH Fully Enrolled Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates. "I am pleased by the meaningful pro
CAHmelia-203 Approaching 50% Enrollment; CAHmelia-204 Recently Surpassed 25% Enrollment Appointment of Saba Sile, M.D., as Vice President of Clinical Development Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2022 and provided corporate updates. "The third quarter of 2022 was one of continuous execution and momentum on multiple fronts. We were pleased to have recently surpassed 25% enrollment in our CAHmelia-204 study and are approaching 50% enrollment in our C
Abstract Accepted for Oral Presentation at International Congress of Endocrinology (ICE 2022) Appointment of P.J. Ramtin as Senior Vice President of Business Operations Expansion of Tildacerfont Patent Portfolio Estate with Key Method of Use Patents Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates. "Throughout the second quarter of 2022, we continued to remain focused on clinical study execution. We were pleased to have recently s
25% Enrollment Achieved in CAHmelia-203 Study for Adult Classic CAH; On Track to Report Topline Data in 2H 2023 Debt Facility with Silicon Valley Bank Amended to Provide Up to $10 Million Credit Line in 2022 Tildacerfont Patent Portfolio Estate Expanded with Key Method of Use Patents Libbie Mansell, Ph.D., M.B.A., R.A.C., Appointed Chief Regulatory and Quality Officer Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2022 and provided corporate updates. "Throughout
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Libbie Mansell, Ph.D., M.B.A., R.A.C., has been appointed Chief Regulatory and Quality Officer. Dr. Mansell will be responsible for leading the company's global regulatory affairs and quality strategy. "Dr. Mansell brings extensive regulatory affairs and quality expertise at precisely the right time for Spruce, as we progress tildacerfont through clinical development for adults and children with classic congenital adrenal hyperplasia and women with polycystic ovary synd
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Will Charlton, M.D., M.A.S., has been appointed Chief Medical Officer, and will succeed Rosh Dias, M.D., who has stepped down to pursue other opportunities. Dr. Charlton is a board-certified pediatric endocrinologist with over 15 years of clinical research experience in industry and academia and will lead the company's clinical development and global drug development strategy. "We are pleased to welcome Will as our Chief Medical Officer, and we look forward to his leade
– Samir Gharib, MBA, Promoted to President – Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Dr. Javier Szwarcberg, M.D., MPH, has been appointed Chief Executive Officer and as a member of the board of directors. Samir Gharib, MBA, has been concurrently promoted to President and will continue in his role as Chief Financial Officer. "With his range of leadership and demonstrated success in rare disease drug development, Javier is an excellent fit for Spruce Biosciences as we enter the next chapter of clinical develop
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Mike Grey as interim Chief Executive Officer, effective immediately. Mr. Grey currently serves as Executive Chairman of the Spruce Board, and will succeed Richard King, who is retiring after a 35-year career in the life sciences industry. Mr. King will remain a strategic advisor to the company through December 31, 2021. Spruce's Board will initiate a candidate search to identify a permanent Chief Executive Officer. "On behalf of the entire Board, I want to
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13D/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13D/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13D/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13D/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
Guggenheim downgraded Spruce Biosciences from Buy to Neutral
Leerink Partners downgraded Spruce Biosciences from Outperform to Market Perform and set a new price target of $2.00 from $9.00 previously
RBC Capital Mkts downgraded Spruce Biosciences from Outperform to Sector Perform and set a new price target of $2.00 from $9.00 previously
Ladenburg Thalmann downgraded Spruce Biosciences from Buy to Neutral
H.C. Wainwright downgraded Spruce Biosciences from Buy to Neutral
Guggenheim initiated coverage of Spruce Biosciences with a rating of Buy and set a new price target of $10.00
Ladenburg Thalmann initiated coverage of Spruce Biosciences with a rating of Buy and set a new price target of $6.00
Oppenheimer initiated coverage of Spruce Biosciences with a rating of Outperform and set a new price target of $15.00
Benchmark initiated coverage of Spruce Biosciences with a rating of Speculative Buy and set a new price target of $7.00
The Benchmark Company initiated coverage of Spruce Biosciences with a rating of Speculative Buy and set a new price target of $7.00
Oppenheimer analyst Hartaj Singh maintains Spruce Biosciences (NASDAQ:SPRB) with a Outperform and lowers the price target from $4 to $3.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) with a Neutral.
Spruce Biosciences Inc. (NASDAQ:SPRB) and HMNC Brain Health GmbH have collaborated to develop Spruce’s investigational product candidate, tildacerfont, and HMNC’s companion diagnostic, the proprietary Cortibon Genetic Selection Tool for major depressive disorder (MDD). Spruce Biosciences is a late-stage biopharmaceutical company developing its wholly-owned product candidate, tildacerfont, for classic congenital adrenal hyperplasia, polycystic ovary syndrome, and MDD. “We believe that Cortibon has the potential to enable tildacerfont to be advanced as a precision therapeutic for personalized medicine in patients with MDD,” said Javier Szwarcberg, CEO of Spruce Biosciences. “Hyperactive
Significant Reduction in Dehydroepiandrosterone Sulfate (DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels at Baseline Increase in Serum Sex Hormone Binding Globulin (SHBG) Versus Placebo Observed Tildacerfont was Well-Tolerated with No Safety Signals
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) with a Neutral.
Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 3.45 percent. This is a 30 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $2.02 million which beat the analyst consensus estimate of $1.16 million by 74.14 percent. This is a 2.85 percent increase over sales of $1.96 million the same period last year.
Spruce Biosciences Inc (NASDAQ:SPRB) shares plummeted on Thursday after the company released topline results from its CAHmelia-203 Phase 2b study of tildacerfont in adult classic congenital adrenal hyperplasia (CAH) and its CAHptain-205 study of tildacerfont in pediatric classic CAH. The CAHmelia-203 study did not achieve the primary efficacy endpoint of the assessment of dose response for the change in A4 from baseline to week 12. The preliminary pharmacokinetic analysis of the CAHptain-205 study suggests that tildacerfont is cleared more rapidly in children than in adult CAH patients. HC Wainwright notes that despite considering tildacerfont an active drug, the setback in the CAHm
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.35% to 38,905.20 while the NASDAQ fell 0.13% to 16,156.28. The S&P 500 also fell, dropping, 0.25% to 5,152.46. Check This Out: Tesla To $165? Here Are 10 Top Analyst Forecasts For Thursday Leading and Lagging Sectors Energy shares jumped by 0.8% on Thursday. In trading on Thursday, real estate shares fell by 2.4%. Top Headline Dick’s Sporting Goods Inc (NYSE:DKS) reported better-than-expected fourth-quarter results and issued strong guidance. Dick’s Sporting Goods reported fourth-quarter FY23 sales growth of 7.8% year-on-year to $3
Shares of Limbach Holdings, Inc. (NASDAQ:LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. Limbach said it sees FY24 revenue of $510 million to $530 million, versus market estimates of $541.1 million. Limbach shares dipped 14.7% to $42.42 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Aptorum Group Limited (NASDAQ:APM) shares climbed 91% to $8.27. Presto Automation Inc. (NASDAQ:PRST) shares jumped 65.2% to $0.3715 after jumping 15% on Wednesday. Cheer Holding, Inc. (NASDAQ:CHR) surged 43.3% to $3.77 following full year 2023 financial results.